Here we should note that other diseases, such as Parkinson’s Disease (73–75) and late-stage liver cancer (68, 72, 76) exhibit increased NPTX2 levels; thus, NPTX2 modulators are needed. This evidence concerns the gene NPTX2 and liver cancer.